Therapeutic Asset Ratings

534 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
au-007 Cancer	Aulos Bioscience, Inc.	P1/2	CC (40)
Avzo-021 Cancer	Avenzo Therapeutics, Inc.	P1/2	CC (40)
Blu-924 Cancer	Blueprint Medicines Corporation	P1/2	CC (40)
bnt3212 Cancer	BioNTech SE	P1/2	CC (40)
bnt326 Cancer	BioNTech SE	P1/2	CC (40)
bnt327 Cancer	DualityBio Inc.	P1/2	CC (40)
Bpi-1178 Cancer	Beta Pharma (Suzhou) Co., Ltd.	P1/2	CC (40)
bt7480 Cancer	BicycleTx Limited	P1/2	CC (40)
Cafelkibart Advanced Solid Tumor	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1/2	CC (40)
can1012 Cancer	Canwell Biotech Limited	P1/2	CC (40)
Cjrb-101 Cancer	CJ Bioscience, Inc.	P1/2	CC (40)
Clio-8221 Cancer	Callio Therapeutics	P1/2	CC (40)
CM350 Cancer	Keymed Biosciences Co.Ltd	P1/2	CC (40)
CONTELTINIB Cancer	Shouyao Holdings (Beijing) Co. LTD	P1/2	CC (40)
db-1202 Cancer	DualityBio Inc.	P1/2	CC (40)
db-1305/bnt325 Cancer	DualityBio Inc.	P1/2	CC (40)
ds-3939a Cancer	Daiichi Sankyo	P1/2	CC (40)
Eis-12656 Cancer	Eisbach Bio GmbH	P1/2	CC (40)
Envafolimab Cancer	IR INNOVATE RESEARCH PRIVATE LIMITED	P1/2	CC (40)
Epsametostat Cancer	Haihe Biopharma Co., Ltd.	P1/2	CC (40)
FB849 Cancer	1ST Biotherapeutics, Inc.	P1/2	CC (40)
Gecacitinib Cancer	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (40)
gen1286 Cancer	Genmab	P1/2	CC (40)
gi-101a Cancer	GI Innovation, Inc.	P1/2	CC (40)
gi-102 Cancer	GI Innovation, Inc.	P1/2	CC (40)

Showing 126 to 150 of 534 assets